AU2022342095A1 - Methods of treating cns disorders - Google Patents

Methods of treating cns disorders Download PDF

Info

Publication number
AU2022342095A1
AU2022342095A1 AU2022342095A AU2022342095A AU2022342095A1 AU 2022342095 A1 AU2022342095 A1 AU 2022342095A1 AU 2022342095 A AU2022342095 A AU 2022342095A AU 2022342095 A AU2022342095 A AU 2022342095A AU 2022342095 A1 AU2022342095 A1 AU 2022342095A1
Authority
AU
Australia
Prior art keywords
disorder
disease
group
alkyl
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022342095A
Other languages
English (en)
Inventor
Congxin Liang
Wei Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Highlightll Pharmaceutical Co Ltd
Original Assignee
Hangzhou Highlightll Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Highlightll Pharmaceutical Co Ltd filed Critical Hangzhou Highlightll Pharmaceutical Co Ltd
Publication of AU2022342095A1 publication Critical patent/AU2022342095A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022342095A 2021-09-13 2022-08-22 Methods of treating cns disorders Pending AU2022342095A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111069990.0 2021-09-13
CN202111069990 2021-09-13
PCT/CN2022/113807 WO2023035913A1 (en) 2021-09-13 2022-08-22 Methods of treating cns disorders

Publications (1)

Publication Number Publication Date
AU2022342095A1 true AU2022342095A1 (en) 2024-06-27

Family

ID=85506085

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022342095A Pending AU2022342095A1 (en) 2021-09-13 2022-08-22 Methods of treating cns disorders

Country Status (8)

Country Link
US (1) US20250032465A1 (https=)
EP (1) EP4419101A4 (https=)
JP (1) JP2024543198A (https=)
CN (2) CN116490180B (https=)
AU (1) AU2022342095A1 (https=)
CA (1) CA3239065A1 (https=)
IL (1) IL313097A (https=)
WO (1) WO2023035913A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023244611A1 (en) * 2022-06-13 2023-12-21 Emory University Uses of jak inhibitors in the management of inflammation-associated depression and central nervous system (cns) pathologies
CN120152713A (zh) * 2022-07-29 2025-06-13 昂胜医疗科技公司 三环芳基衍生物及其组合物和方法
WO2025224600A1 (en) 2024-04-21 2025-10-30 Biohaven Therapeutics Ltd. Treatment of alpha-synucleinopathies and neuroprotection
WO2025248468A1 (en) * 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria)
WO2026032213A1 (zh) * 2024-08-08 2026-02-12 普罗思特(南京)生物科技有限公司 取代的三环衍生物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2473579B (en) * 2008-06-30 2013-01-30 Biotechnology Res Corp Ltd Stat3 and TYK2 as drug targets for neurodegenerative diseases
CN105636962B (zh) * 2013-10-15 2017-10-13 靳博涵 新型化合物、用途及其制备方法
MX390005B (es) * 2016-10-03 2025-03-20 Hangzhou Highlightll Pharmaceutical Co Ltd Inhibidores selectivos de jak1 novedosos y usos de los mismos.
BR112021024533A2 (pt) 2019-06-06 2022-01-18 Highlightll Pharmaceutical Hainan Co Ltd Método de síntese de composto de furoimidazopiridina, forma cristalina de composto de furoimidazopiridina, e forma cristalina de sal do mesmo
WO2020244349A1 (zh) * 2019-06-06 2020-12-10 广州高瓴制药有限公司 呋喃并咪唑并吡啶类化合物的合成方法、多晶型物、及盐的多晶型物

Also Published As

Publication number Publication date
JP2024543198A (ja) 2024-11-19
US20250032465A1 (en) 2025-01-30
CN116490180B (zh) 2024-03-22
CN118059096A (zh) 2024-05-24
EP4419101A1 (en) 2024-08-28
CA3239065A1 (en) 2023-03-16
IL313097A (en) 2024-07-01
EP4419101A4 (en) 2025-09-03
WO2023035913A1 (en) 2023-03-16
CN116490180A (zh) 2023-07-25

Similar Documents

Publication Publication Date Title
US12209076B2 (en) Imidazolyl kinase inhibitors and uses thereof
WO2023035913A1 (en) Methods of treating cns disorders
US11406645B2 (en) Acetamide thienotriazolodiazepines and uses thereof
US10457691B2 (en) Macrocyclic kinase inhibitors and uses thereof
US10793571B2 (en) Uses of diazepane derivatives
US10308653B2 (en) Diazepane derivatives and uses thereof
US20160347750A1 (en) Dihydropteridinone derivatives and uses thereof
US20160347749A1 (en) Diazepane derivatives and uses thereof
US11306105B2 (en) Cyano thienotriazolodiazepines and uses thereof
US9951074B2 (en) Dihydropteridinone derivatives and uses thereof
US12486289B2 (en) Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof
HK40094824A (zh) 治疗cns病症的方法
HK40094824B (zh) 治疗cns病症的方法
HK40108558A (zh) 治疗cns病症的方法

Legal Events

Date Code Title Description
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 13 JUN 2024